Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Kindred Biosciences Inc. Stories

2014-04-08 16:23:29

SAN FRANCISCO, April 8, 2014 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the closing of its public offering of 3,450,000 shares of its common stock, including 450,000 shares sold pursuant to the exercise in full by the underwriters of their over-allotment option, at a public offering price of $18.00 per share. Kindred Bio estimates net proceeds from the offering to be...

2014-04-04 08:25:56

SAN FRANCISCO, April 4, 2014 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will present at Needham 13(th) Annual Healthcare Conference in New York City: Presentation date: April 9, 2014 Presenting time: 12:10 PM ET Presentation location: Westin Grand Central Hotel, Ambassador Room The presentation will be webcast live over the Internet and can be accessed through the...

2014-04-03 08:31:26

SAN FRANCISCO, April 3, 2014 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of its public offering of 3,000,0000 shares of its common stock at a public offering price of $18.00 per share, for a total offering amount of $54,000,000 before deducting underwriting discounts and commissions and estimated offering expenses payable by Kindred Bio, upsized from the previously...

2014-03-31 16:27:17

SAN FRANCISCO, March 31, 2014 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the commencement of its public offering of approximately $50 million of shares of common stock pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission. The number of shares to be offered and the public offering price have not yet been determined. Leerink...

2014-03-31 08:31:02

SAN FRANCISCO and WALTHAM, Mass., March 31, 2014 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN) and X-Body Biosciences (X-Body) jointly announced today an exclusive alliance in which X-Body will discover fully canine, feline, and equine antibodies for companion animal health, and Kindred Bio will develop and commercialize these antibodies. Kindred Bio will provide an upfront payment, research funding, milestones, and royalties, and X-Body will exclusively license these...

2014-03-28 08:27:31

SentiKin(TM), Kindred Bio's third lead product candidate, is being developed for the treatment of post-operative pain in dogs. SAN FRANCISCO, March 28, 2014 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated the pivotal clinical trial for SentiKin (KIND-009) for post-operative pain in dogs. SentiKin is a centrally acting non-opioid, non-steroidal...

2014-03-24 08:29:59

Blake Hawley, D.V.M., Worldwide Director of Global Digital and Former General Manager of U.K. & Ireland, Russia, Central Eastern Europe, and Australasia at Hill's Pet Nutrition, to Join Kindred Bio SAN FRANCISCO, March 24, 2014 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN) announced today that it has appointed Blake Hawley, D.V.M., as its Chief Commercial Officer. Separately, it also announced that it expects to be added to several Russell indexes on March 31, 2014. Dr....

2014-03-18 16:25:53

SAN FRANCISCO, March 18, 2014 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed follow-on public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Leerink Partners LLC will act as lead...

2014-03-06 08:31:18

SAN FRANCISCO, March 6, 2014 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the fourth quarter and year ended December 31, 2013. Kindred Bio will host a webcast and conference call at 1:30 p.m. (PT) this afternoon to review its corporate progress and financial results. Richard Chin, M.D., Kindred Bio's President and Chief Executive Officer, noted that "We had a successful 2013, with recruitment of a strong management team, advancement of our...

2014-03-04 12:25:47

SAN FRANCISCO, March 4, 2014 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will present at Roth Capital Partners 26(th) Annual Growth Stock Conference in Dana Point, CA: Presentation date: March 10, 2014 Presenting time: 1:30 PM PDT Presentation location: Ritz-Carlton, Salon 6 The presentation will be webcast live over the Internet and can be accessed...